Physician profile
Indira Bashic
NPI 1033666904
$1,245.53
in general payments reported to CMS, 2019-2025
12 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.35 · 2022: $29.41 · 2023: $100 · 2024: $575 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $372.43 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $251.34 | 2025 | Inspire |
| Sage Therapeutics, LLC | $115.47 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.03 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $99.10 | 2024 | Airsupra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.61 | 2024 | |
| Merck Sharp & Dohme LLC | $55.35 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $38.12 | 2022-2023 | Rexulti |
| Amgen INC. | $34.25 | 2021-2023 | Otezla, Repatha |
| Abbvie INC. | $32.56 | 2024-2025 | |
| Indivior INC. | $32.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.11 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Bashic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.